Informing Oral Nicotine Pouch Regulations to Promote Public Health

Part of paid clinical trials in Columbus, Ohio.

Sponsor
Ohio State University Comprehensive Cancer Center
Study ID
NCT06315881
Phase
PHASE2
Status
Recruiting

Conditions

  • Tobacco-Related Carcinoma

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Biospecimen Collection — PROCEDURE
    Undergo blood sample and oral mucosa sample collection
  • Cigarette — DRUG
    Smoke usual brand cigarette
  • Nicotine Oral Pouch — DRUG
    Insert low FBN R/S ONP
  • Nicotine Oral Pouch — DRUG
    Insert low FBN \> 99% S ONP
  • Nicotine Oral Pouch — DRUG
    Insert high R/S ONP
  • Nicotine Oral Pouch — DRUG
    Insert high FBN \> 99% ONP
  • Smokeless Tobacco — DRUG
    Insert ST
  • Survey Administration — OTHER
    Ancillary studies
  • Text Message-Based Navigation Intervention — OTHER
    Receive text with a link to daily diary surveys

Study Details

This clinical trial evaluates the characteristics of oral nicotine pouches (ONPs) to determine if they are a comparable substitute to cigarette or smokeless tobacco (ST) products. ONPs contain nicotine but no tobacco and are used primarily by adult tobacco uses in the United States (US). ONPs are recognized by the Food and Drug Administration as having lower risk than combustible cigarettes and are approved as a modified risk tobacco product. While ONPs have lower toxic risk than other tobacco products, acute and longer term harm related to their use has not been studied. Information gathered from this study may identify product characteristics of ONPs that improve successful switching from high-risk cigarettes or ST to lower risk ONPs.

Key Dates

Start date
Jan 13, 2025
Status verified
Apr 2026
Primary completion
Jan 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
160 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: PHASE I ARM I (low FBN R/S ONP)
    Participants insert low free-base nicotine (FBN) R/S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
  • Experimental: PHASE I ARM II (low FBN > 99% S ONP)
    Participants insert low FBN \> 99% S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
  • Experimental: PHASE I ARM III (high FBN R/S ONP)
    Participants insert high R/S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
  • Experimental: PHASE I ARM IV (high FBN > 99% ONP)
    Participants insert high FBN \> 99% S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
  • Experimental: PHASE I ARM V (Usual brand ST or cigarette)
    Participants insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes. Patients also undergo blood sample collection at 0, 5, 15, 30, 60, and 90 minutes.
  • Experimental: PHASE II ARM I (low FBN R/S ONP)
    WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week. CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use. Participants insert low FBN R/S ONP for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection.
  • Experimental: PHASE II ARM II (low FBN > 99% S ONP)
    WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week. CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use. Participants insert to low FBN \> 99% S ONP product for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection.
  • Experimental: PHASE II ARM III (high R/S ONP)
    WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week. CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use. Participants insert to high R/S ONP product for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection.
  • Experimental: PHASE II ARM IV (high FBN > 99% ONP)
    WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week. CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use. Participants insert high FBN \> 99% S ONP product for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection.

Primary Outcome Measure

Increased nicotine delivery [ Time Frame: Up to 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ohio State University Comprehensive Cancer CenterColumbusOhio43210
Brittney L. Keller-Hamilton, PhD, MPH
614-366-9652
Brittney L. Keller-Hamilton, PhD, MPH (PRINCIPAL_INVESTIGATOR)

Find similar trials in Columbus, OH

Related Studies